What evidence supports the use of medications for alcohol use disorder?

Evidence-Based Medications for Alcohol Use Disorder

For patients with alcohol use disorder, naltrexone (50 mg/d oral) or acamprosate (2-3 g/d) combined with counseling are first-line pharmacotherapies with the strongest evidence for maintaining abstinence and reducing heavy drinking. 1, 2

Primary Pharmacotherapy Options

First-Line Medications (Class I, Level A Evidence)

Naltrexone (50 mg/d oral):

• Reduces craving by blocking opioid receptors
• Number needed to treat (NNT) = 18 to prevent return to any drinking 2
• NNT = 11 to prevent return to heavy drinking 2
• Critical caveat: Contraindicated in severe liver disease due to hepatotoxicity risk 3
• However, recent evidence suggests it may be safe even in severe cirrhosis when benefits outweigh risks 4
• Common side effects: nausea (RR 1.73) and vomiting (RR 1.53) 2

Acamprosate (2-3 g/d):

• Modulates glutamatergic receptors, reduces withdrawal symptoms and craving
• NNT = 11 to prevent return to any drinking 2
• Key advantage: Safe in liver disease—no dose adjustment needed 3, 5
• Most effective for maintaining rather than inducing abstinence 1
• Must be started after detoxification, not during active drinking 1
• Requires 1-2 weeks to reach therapeutic levels 6
• Dose: 1,998 mg/day for patients ≥60 kg; reduce by one-third if <60 kg 6

Second-Line Options

Disulfiram (250-500 mg/d):

• Limited evidence for efficacy despite FDA approval 1
• Avoid in severe liver disease due to hepatotoxicity 3
• Poor tolerability has led to replacement by newer agents 1

Baclofen (30 mg/d, up to 80 mg/d):

• GABA-B receptor agonist
• Unique advantage: Only medication specifically studied in cirrhotic patients 1, 3
• Safe in advanced liver disease 5, 6
• Reduces craving and maintains abstinence in cirrhosis 1
• Gradual dose escalation recommended in severe liver disease 5

Emerging Evidence

Topiramate:

• Shows promise for reducing heavy drinking 3
• Decreases liver enzyme levels 3
• Not yet tested specifically in alcoholic liver disease patients 3

Injectable Naltrexone:

• Reduces drinking days by approximately 5 days per month (weighted mean difference -4.99 days) 2
• May improve adherence compared to oral formulation

Semaglutide (GLP-1 agonist):

• Recent 2025 trial shows reduction in alcohol consumption and craving 7
• Reduced drinks per drinking day and heavy drinking episodes 7
• Requires larger trials before clinical recommendation

Treatment Algorithm

For Patients WITHOUT Liver Disease:

1. First choice: Naltrexone 50 mg/d OR Acamprosate 2-3 g/d
2. Both equally effective; choose based on:
   • Naltrexone: Better for reducing heavy drinking episodes
   • Acamprosate: Better for complete abstinence maintenance
3. Always combine with counseling/psychosocial support 1

For Patients WITH Alcoholic Liver Disease:

1. Mild-moderate liver disease: Acamprosate (no dose adjustment needed) 3, 5
2. Severe liver disease/cirrhosis:
   • First choice: Baclofen 30-80 mg/d 5, 6
   • Alternative: Acamprosate (remains safe) 5
   • Avoid: Naltrexone, disulfiram (hepatotoxicity risk) 3
   • Exception: Naltrexone may be considered case-by-case in severe disease when benefits outweigh risks 5, 4

For Alcohol Withdrawal Syndrome:

• Gold standard: Benzodiazepines 3, 6, 3
• Long-acting (diazepam, chlordiazepoxide) for seizure/delirium prevention
• Short-acting (lorazepam, oxazepam) safer in elderly and hepatic dysfunction 3
• Always provide thiamine 100-500 mg/d to prevent Wernicke encephalopathy 6

Critical Implementation Points

Timing matters:

• Acamprosate: Start 3-7 days after last drink, after withdrawal resolves 6
• Naltrexone: Can initiate with or without prior withdrawal 4
• Both require 1-2 weeks for therapeutic effect 6

Combination with psychosocial treatment is essential:

• Medications alone are insufficient 1, 8
• Cognitive behavioral therapy plus pharmacotherapy superior to usual care 8
• Brief motivational interventions should be routine 3

Common prescribing pitfalls:

• Underutilization: <3% of AUD patients receive pharmacotherapy in Australia 4
• Failure to continue medications long enough (minimum 3-6 months, up to 12 months) 6
• Not adjusting for liver disease severity
• Prescribing naltrexone reflexively without liver function assessment

Comparative Efficacy Summary

A 2022 network meta-analysis 9 found the following medications improved total abstinence over placebo (in order of effect size):

1. Gamma-hydroxybutyrate (RR 1.90)
2. Baclofen (RR 1.80)
3. Disulfiram (RR 1.71)
4. Gabapentin (RR 1.66)
5. Acamprosate (RR 1.33)
6. Oral naltrexone (RR 1.15)

For reducing heavy drinking, disulfiram showed the largest effect (RR 0.19), followed by baclofen (RR 0.72), acamprosate (RR 0.78), and naltrexone (RR 0.81) 9.

However, the 2023 JAMA meta-analysis 2 provides the most robust recent evidence supporting naltrexone and acamprosate as first-line agents with the best balance of efficacy, safety, and clinical applicability.

The most recent 2022 French guidelines 5 emphasize that naltrexone, nalmefen, and disulfiram contraindications in hepatic insufficiency are not supported by solid literature data and should be assessed case-by-case, though acamprosate and baclofen remain preferred in advanced liver disease.